Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07120503 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
A Phase 2 study of Asthma (Diagnosis), sponsored by Windward Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 20
- Study locations
NCT07120503: Recruiting Phase 2 study of Asthma (Diagnosis), sponsored by Windward Bio.
NCT07120503 is a Phase 2 study of Asthma (Diagnosis) that is actively recruiting participants, run by Windward Bio. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07120503, a Phase 2 study of Asthma (Diagnosis), is actively recruiting participants, sponsored by Windward Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate or severe asthma. WIN378 blocks the action of a protein called TSLP which causes inflammation in the lung and may contribute to your asthma control and symptoms. The study will test how doses of WIN378 are handled by your body (pharmacokinetics) and assess the safety of the medicine and will assess markers of asthma inflammation in your breath and in your blood, lung function and asthma control (pharmacodynamics).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG WIN378
Study Locations (20)
Texas
- WB Contracted Clinical Research Site - Austin
- WB Contracted Clinical Research Site - El Paso
- WB Contracted Clinical Research Site - McKinney
- WB Contracted Clinical Research Site - San Antonio
- WB Contracted Clinical Research Site - Tyler
California
- WB Contracted Clinical Research Site - Los Angeles
- WB Contracted Clinical Research Site - San Jose
Florida
- WB Contracted Clinical Research Site - Melbourne
- WB Contracted Clinical Research Site - Miami
South Carolina
- WB Contracted Clinical Research Site - Charleston
- WB Contracted Clinical Research Site - Spartanburg
Buenos Aires F.D.
- WB Contracted Clinical Research Site - Buenos Aires
- WB Contracted Clinical Research Site - Buenos Aires
Maryland
- WB Contracted Clinical Research Site - White Marsh
Minnesota
- WB Contracted Clinical Research Site - Richfield
Missouri
- WB Contracted Clinical Research Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT07120503 shows while recruiting
NCT07120503 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Asthma (Diagnosis) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07120503 names 20 study sites across 12 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07120503 about?
NCT07120503 is a clinical study titled "Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma". This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate or severe asthma. WIN378 blocks the action of a protein called TSLP which causes inflammation in the lung and may contribute to your asthma control and symptoms. The study will test how d...
What is the current status of trial NCT07120503?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2025-07-24. Estimated completion is 2027-10.
What conditions does trial NCT07120503 study?
This clinical trial studies the following conditions: Asthma (Diagnosis).
What interventions are being tested in trial NCT07120503?
The interventions under investigation include: Placebo (DRUG), WIN378 (DRUG).
Who is sponsoring clinical trial NCT07120503?
This trial is sponsored by Windward Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07120503 being conducted?
This trial has 20 study locations across California, Florida, Maryland, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma (Diagnosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07120503's enrollment target sits among peer trials
136 527th of 2000 higher than 1,470 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI